Myelodysplastic Syndrome Clinical Trials
Here are the 6 most popular medical studies for myelodysplastic syndrome
Alkylating agents
Cyclophosphamide +7 More for Leukemia
This trial is studying four different chemotherapy regimens given with or without total-body irradiation before umbilical cord blood transplant to see how well they work in treating patients with relapsed or refractory hematologic cancer.
Alkylating agents
Chemoradiotherapy + Stem Cell Transplant for Blood Cancers
This trial is giving chemotherapy drugs and HT before a donor stem cell transplant to see if it helps stop the growth of cancer cells and also helps stop the patient's immune system from rejecting the donor's stem cells.
Alkylating agents
IM-TMI + Chemotherapy for AML and MDS
This trial is testing whether adding a new kind of radiation to the standard myeloablative fludarabine/ i.v. targeted busulfan conditioning improves outcomes for patients receiving allogeneic hematopoietic stem cell transplant (HSCT).
Popular filter options for myelodysplastic syndrome trials
MDS Clinical Trials
View 89 MDS medical studies.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
Myelomonocytic Leukemia Clinical Trials
View 89 Myelomonocytic Leukemia medical studies.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
HLA Positive Clinical Trials
View 8 HLA positive medical studies.
CAR T-cell Therapy
Gene Modified T-cells for Blood Disorders
This trial will look at whether T cells from a family member can help a patient's immune system recover after a stem cell transplant, with the added safety measure of a self-destruct switch.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
HLA-A Positive Clinical Trials
View 8 HLA-A positive medical studies.
CAR T-cell Therapy
Gene Modified T-cells for Blood Disorders
This trial will look at whether T cells from a family member can help a patient's immune system recover after a stem cell transplant, with the added safety measure of a self-destruct switch.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Phase 3 Myelodysplastic Syndrome Clinical Trials
View 89 phase 3 myelodysplastic syndrome medical studies.
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Monoclonal Antibodies
MBG453 + Azacitidine for Myelodysplastic Syndrome
This trial is a Phase III, randomized, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult subjects with intermediate, high or very high risk myelodysplastic syndrome or Chronic Myelomonocytic Leukemia-2.
Anti-metabolites
Cedazuridine + Azacitidine for Leukemia
This trial is designed to test a new treatment for leukemia that is taken orally. The first phase will test different doses to find the best one. The second phase will compare the new treatment to the standard one given by injection. The third phase will test the best oral dose against the standard injection dose.
Myelodysplastic Syndrome Clinical Trials With No Placebo
View 89 myelodysplastic syndrome medical studies that do not have a placebo group.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
View More Myelodysplastic Syndrome Trials
See another 66 medical studies focused on myelodysplastic syndrome.
Frequently Asked Questions
Introduction to myelodysplastic syndrome
What are the top hospitals conducting myelodysplastic syndrome research?
When it comes to advancing the treatment options for myelodysplastic syndrome, several top hospitals across the United States are leading the way. In Boston, renowned institutions like Dana Farber Cancer Institute and Massachusetts General Hospital have dedicated considerable efforts to combat this condition. Dana Farber Cancer Institute currently has 13 active clinical trials focusing on myelodysplastic syndrome, building upon their extensive repertoire of 42 past trials since their first recorded trial in 2001. Similarly, Massachusetts General Hospital is making notable progress with seven ongoing trials and an impressive history of 47 previous studies dating back to their earliest involvement in researching this disorder in 1984.
Meanwhile, University of Miami in sunny Miami and Washington University School of Medicine in Saint Louis are also integral players when it comes to pushing boundaries against myelodysplastic syndrome. The former institution is conducting seven active clinical trials while having completed a total of 16 successful investigations since embarking on this journey in 2006. On the other hand, Washington University School of Medicine boasts six ongoing clinical tests and a commendable track record of contributing towards understanding myelodysplastic syndrome through their involvement in around41 earlier trials commencing from as early as2003.
Notably adding itself into this prestigious group is Fred Hutchinson Cancer Research Center situated amidst Seattle's vibrant atmosphere; they too conduct research regarding MDS (MyeloDySPlastic Syndrome) via actively performing six current experimental divisions along with being recognized globally for having taken partin eighty-five previous experiments that commenced from1991 onwards.
These esteemed institutions not only provide hope for individuals affected by myelodysplastic syndrome but also symbolize the tireless pursuit towards unraveling mysteries surrounding this condition nationwide. By collaborating together and pioneering innovative clinical trials, these hospitals bring us one step closer each day towards finding effective treatments and improving lives impacted by MDS
Which are the best cities for myelodysplastic syndrome clinical trials?
When it comes to myelodysplastic syndrome clinical trials, several cities stand out as top contenders for research and development. Boston, Massachusetts leads the pack with 36 active trials focusing on treatments like H3B-8800 (RVT-2001) Dose Escalation, Venetoclax, and Inqovi. Following closely behind is Houston, Texas with 27 ongoing studies exploring therapies such as BGB-11417 and CC-95251. New york City also plays a significant role in advancing treatment options with 20 active trials investigating interventions like Bone Marrow Hematopoietic Stem Cell Transplantation and Oral Azacitidine. Other notable cities include Miami, Florida with 19 active trials and Chicago, Illinois with 17 active trials. These cities offer individuals affected by myelodysplastic syndrome access to cutting-edge clinical trials that have the potential to transform care outcomes significantly.
Which are the top treatments for myelodysplastic syndrome being explored in clinical trials?
In the world of myelodysplastic syndrome research, several promising treatments are making waves in ongoing clinical trials. CPX-351 stands out with its involvement in two active trials and a total of 11 past trials dedicated to this condition since its introduction in 2009. Another contender is luspatercept, currently being explored in two active studies and having been listed for myelodysplastic syndrome research since 2016 with a cumulative count of 15 trials. Also on the radar is MBG453, showing potential through participation in two ongoing trials and seven historical ones since its listing in 2017. Lastly, atorvastatin enters the fray with two current investigations and three prior myelodysplastic syndrome clinical trials after joining the scene just recently in 2018. As researchers delve deeper into these avenues of exploration, new hope emerges for individuals battling myelodysplastic syndrome worldwide.
What are the most recent clinical trials for myelodysplastic syndrome?
Exciting progress is being made in the realm of myelodysplastic syndrome, with recent clinical trials offering hope and potential advancements for patients. Among these trials is the investigation of Sitagliptin + Bortezomib + Cyclophosphamide as a treatment option, showing promise in Phase 1 and Phase 2 studies. Additionally, a Phase 2 trial explores CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplantation utilizing the Busulfan/Melphalan/Fludarabine Regimen to address this condition. Itacitinib has also emerged as an area of interest in a Phase 1 study for myelodysplastic syndrome. Another trial focuses on Cy/Flu/TBI paired with Post-transplant CY therapy. Lastly, Dose Escalation Cohorts are being analyzed across Phases 1 and 2 to assess their efficacy against myelodysplastic syndrome. These endeavors signify significant strides towards improved outcomes for individuals affected by this disorder.
What myelodysplastic syndrome clinical trials were recently completed?
In recent years, a plethora of clinical trials have been conducted to advance the understanding and treatment options for myelodysplastic syndrome (MDS). Noteworthy completed trials include the investigation of Lemzoparlimab by AbbVie in June 2021, sabatolimab by Novartis Pharmaceuticals in May 2021, Azacitidine by Pfizer in May 2021. Other notable studies encompassed Salsalate by Rutgers University in October 2020, Recombinant Interleukin-7 by M.D. Anderson Cancer Center in September 2020, PRT1419 by Prelude Therapeutics also in September 2020, and CB-5339 by Cleave Therapeutics Inc. in June 2020. These comprehensive efforts collectively contribute towards advancing therapeutic strategies for individuals affected by MDS - a condition characterized by impaired blood cell production primarily affecting older adults.